Sequenom News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.12.17	Unit 7 Consulting Recognized for National Sales Efforts (PR Newswire)
27.09.17	Austin Based Primizie Snacks Wins SELF Magazine's Healthy Food Awards (PR Newswire)
23.11.16	Princess Cruises Announces Largest Ever Fall Deployment in Canada & New England (PR Newswire)
04.10.13	Pre-Market Analysis: Inovio Pharmaceuticals Inc., Sequenom Inc., and Optimer Pharmaceuticals Inc. (PR Newswire)
03.10.13	Sequenom Files Premarket 510(k) Notification With FDA For IMPACT Dx™ System (PR Newswire)
01.10.13	Merger Updates, Milestone Payments, AGM Results, Review of Strategic Alternatives and Other Corporate Announcements - Research Report on Cubist, Halozyme, Taro, Galena and Sequenom (PR Newswire)
23.09.13	Sequenom Announces Review Of Strategic Alternatives For Its Genetic Analysis Business Segment (PR Newswire)
18.09.13	Sequenom Announces Global Certified Service Provider Program (PR Newswire)
10.09.13	Harwood Feffer LLP Announces Investigation of Sequenom Inc. (PR Newswire)
29.08.13	Today's Research: Inovio Pharmaceuticals Inc., Onyx Pharmaceuticals Inc., Sequenom Inc. and Optimer Pharmaceuticals Inc. (PR Newswire)
15.08.13	Pharma Companies Announce Investments in R&D, Ongoing Clinical Trials and Financial Results - Research Report on Alnylam, Infinity, Nektar, Sequenom, and Merrimack (PR Newswire)
12.08.13	Financial Results Release, Management Changes, and Newly Issued Permits - Research Report on Valeant, Teva, Endo, Array, and Sequenom (PR Newswire)
07.08.13	Sequenom Announces Participation At The Wedbush 2013 Life Sciences Management Access Conference (PR Newswire)
05.08.13	Sequenom CMM's MaterniT21™ PLUS Testing Service Received Clinical Laboratory Permit From New York State (PR Newswire)
01.08.13	Sequenom And CombiMatrix Announce Collaboration Agreement To Market Chromosomal Microarray Analysis For Prenatal Testing (PR Newswire)
24.07.13	Today's Technical View: Inovio Pharma, Sequenom, Onyx Pharma, and Optimer Pharma (PR Newswire)
04.03.09	Sequenom Adopts Share Purchase Rights Plan (Businesswire)
11.02.09	Sequenom Reports Fourth Quarter Financial Results (Businesswire)
29.01.09	Sequenom Announces New Positive Data on Down Syndrome Detection and Unveils Breakthrough DNA Approach to Prenatal Diagnostics (Businesswire)
28.01.09	Sequenom Center for Molecular Medicine Collaborates with Obstetrix Medical Group to Provide Clinical Samples for LDT Validation Study (Businesswire)
17.11.08	Sequenom Completes Acquisition of CLIA-Certified Laboratory (Businesswire)
30.10.08	Sequenom Reports 2008 Third Quarter Financial Results (Businesswire)
16.09.08	Sequenom Acquires Exclusive License to Digital PCR and Other Noninvasive Prenatal Diagnostic Intellectual Property (Businesswire)
04.06.08	Sequenom Announces Results of Screening Studies for Down Syndrome and Updates Development of Noninvasive Prenatal Diagnostics at Analyst and Investor Briefing (Businesswire)
09.01.08	MetaMorphix and Sequenom Agree to Build on Success (Businesswire)
27.12.07	Sequenom Announces New York State Approval of a Noninvasive Prenatal Test (Businesswire)
05.11.07	Sequenom to Sponsor Workshop Introducing Prenatal Diagnostics at AMP 2007 Annual Meeting (Businesswire)
31.10.07	Sequenom Reports Third Quarter 2007 Financial Results (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Kuehne+Nagel Int	206.70	2.43 %	K V
UBS Group	31.75	1.99 %	K V
Lonza Grp	563.20	1.59 %	K V
Sika	227.20	1.16 %	K V
Alcon	77.98	1.01 %	K V
Swisscom	512.50	0.00 %	K V
Novartis	89.23	-0.10 %	K V
Swiss Re	135.60	-0.18 %	K V
Swiss Life Hldg	721.80	-0.50 %	K V
Zurich Insur Gr	530.40	-1.67 %	K V

Nachrichten zu Sequenom IncShs

Aktien Top/Flop

Meistgelesene Nachrichten